When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,168,326: What the Claims Cover and How the Landscape Stacks Up

US Patent 10,168,326 claims an interference-suppressed, multi-component immunoassay workflow for measuring anti-drug antibodies (ADAs) against an anti-inflammatory drug antibody used in rheumatoid arthritis (RA), juvenile arthritis (JIA), or osteoarthritis (OA). The claims narrow to: (i) a specific “1:1 lysine-conjugated” capture and tracer reagent architecture, (ii) a defined incubation window and reagent concentrations, (iii) an IgG oligomer supplementation step to suppress assay interference, and (iv) a labeled anti-label detection step that reads out the tracer label.

Where the claim boundaries are tight

The independent claim (Claim 1) is long but it is structurally constrained by four “gates” that any potential design-around must move simultaneously to avoid infringement:

1) Reagent architecture gate

The capture drug antibody reagent and the tracer drug antibody reagent each are 1:1 conjugates via a single lysine residue (the drug antibody is the anti-inflammatory antibody).
Each conjugate is used at 0.5 to 10 µg/mL.

2) Co-incubation and matrix gate

The sample is from RA, JIA, or OA patients treated with the drug antibody.
The sample contains 1% to 20% serum.
The sample is supplemented with oligomeric human IgG to a final concentration of 10 to 1000 µg/mL.
The incubation occurs 0.5 to 24 hours with the capture and tracer conjugates.

3) Complex immobilization gate

The assay immobilizes the formed complex using a binding-pair system: the first member (attached to the capture antibody) is conjugated to a second member on the solid phase.

4) Signal generation gate

The immobilized complex is incubated with an anti-detectable-label antibody (bearing a second detectable label).
The ADA signal is read from the second-labeled anti-label antibody.

Dependent claims add:

Claim 2: patient is RA.
Claim 3-4: binding pair is biotin on the first member and streptavidin on the solid phase; tracer label is digoxygenin.
Claim 5: sample contains ADAs and rheumatoid factors (RFs).
Claim 6-7: drug antibody is anti-IL6R; specifically tocilizumab.

What the Independent Claim is Really Claiming (and What It Is Not)

What exactly is “interference-suppressed” in the claim?

The only interference-suppression mechanism explicitly claimed is oligomeric human IgG supplementation at 10 to 1000 µg/mL prior to incubation. The claim does not require any other interference-reduction technique such as RF-specific blocking agents, heterophile antibody blocking reagents, polyethylene glycol (PEG) precipitation, or wash-stringency regimes.

What assay format is implied

The workflow is a classic bridging immunoassay logic:

ADA in patient sample bridges a capture and tracer drug antibody reagent.
The capture component is immobilized via a binding pair (e.g., biotin-streptavidin).
A labeled anti-label antibody binds to the tracer label (e.g., digoxygenin) and yields signal.

The claim is not generic “ADA assay.” It is a specific implementation that includes:

lysine-based 1:1 conjugation for both capture and tracer reagents,
defined reagent mass concentrations,
defined serum percentage,
defined oligomeric IgG supplementation range,
a binding-pair immobilization architecture,
an anti-label detection step with a second label.

What the claim does not require

The claim does not require:

any specific secondary readout platform (ELISA, electrochemiluminescence, lateral flow),
specific solid-phase material (plates, beads, magnetic particles),
any specific detection chemistry other than “detecting via detectable label signals”,
a particular ADA isotype or specificity profile beyond “anti-drug antibodies against said drug antibody.”

That matters for the patent landscape: if competitors build assays that still use oligomeric IgG interference suppression but change the conjugation chemistry or labeling architecture, they can land outside Claim 1.

Dependent Claim Coverage: How Narrow the Patent gets

Claim 2 (RA-only patient cohort)

Claim 2 narrows the patient group but does not change the assay mechanism. A competitor can potentially avoid Claim 2 by claiming a design that claims use in “JIA and OA” cohorts only, but that is usually not a strong infringement lever unless claims are used to support product labeling or intended-use arguments.

Claim 3-4 (biotin-streptavidin + digoxygenin)

These convert the generic binding-pair concept into a specific pairing and a specific tracer label.

Claim 3: capture binding pair member = biotin; tracer detectable label = digoxygenin.
Claim 4: solid-phase binding pair member = streptavidin.

If a competitor uses another label (e.g., fluorescein, HRP label directly, or alternative hapten systems) or another binding pair (e.g., His-tag/Ni-NTA, Protein A/G systems, or covalent immobilization without biotin-streptavidin), the design can potentially avoid these dependent claims while still testing for RA ADAs.

Claim 5 (ADAs and rheumatoid factors together)

This is a commercial realism clause: RFs exist in RA patient samples and often create assay interference. Claim 5 indicates the assay is used in samples that include both ADAs and RFs. It does not state any RF-clearing step besides oligomeric human IgG supplementation, so it does not broaden the interference suppression mechanism.

Claim 6-7 (anti-IL6R; tocilizumab)

This is the most valuable narrowing because tocilizumab is a major IL-6R biologic with known ADA monitoring markets.

Claim 6: drug antibody is anti-IL6R.
Claim 7: anti-IL6R antibody is tocilizumab.

For landscape analysis, this means the most direct competitive threat is from ADA assay systems built specifically for tocilizumab (and in practice, IL-6R therapies).

Critical Claim Construction: Key Technical Elements Likely to be Fought

Single lysine 1:1 conjugation

The claim requires each of the capture and tracer reagents to be a 1:1 conjugate via a single lysine residue. In practice, this implies:

a site-specific or near-site-specific conjugation strategy,
a defined stoichiometry (one label per antibody, for both capture and tracer conjugates).

This is a central vulnerability for competitors: many ADA assays use heterogeneous conjugation chemistries (random lysine labeling, other residues, variable label-to-antibody ratios). If those are not “1:1 via a single lysine residue,” they may avoid literal infringement.

Dual reagent concentration bands

Both conjugates are used at 0.5 to 10 µg/mL. If competitors run at significantly different concentrations, they may fall outside literal claim bounds. Courts can also interpret ranges as literal; that becomes a factual question tied to assay protocols used in the accused product.

Oligomeric human IgG supplementation range

The final concentration range is 10 to 1000 µg/mL. Assays often use:

nonspecific IgG blockers,
heterophile blockers,
aggregated immunoglobulin blockers,
PEG or other precipitation.

Only one mechanism is claimed in the patent: oligomeric human IgG at the specified range. If a competitor uses a different blocker species (e.g., bovine serum albumin, casein, HAMA blockers, F(ab’)2 fragments, synthetic heterophile blockers), it can avoid.

Anti-detectable-label antibody with a second detectable label

The assay is not a direct-labeled tracer readout. The claim requires:

immobilize the bridge complex,
incubate with an antibody against the detectable label that itself is conjugated to a second detectable label,
detect via that second detectable label.

Many modern platforms read tracer directly (e.g., directly labeled tracer with no anti-hapten step). Those can avoid.

Patent Landscape: How to Read This Claim Set Against Likely Competitors

Which parts of the landscape are most “crowded”?

Crowded areas likely

1) Bridging ADA assays for monoclonal antibodies

Most ADA assays use bridging logic: patient ADA binds two forms of the drug antibody. This part alone is not uniquely patentable.

2) Biotin-streptavidin immobilization

Widely used in immunoassays, often without unique novelty.

3) Hapten label + anti-hapten detection

Systems using digoxygenin or similar hapten labels are also common.

Less crowded, more discriminating areas likely

1) Oligomeric human IgG at 10 to 1000 µg/mL

Interference suppression is common, but the claim pins to a specific blocker identity and concentration band.

2) 1:1 conjugates via a single lysine residue

“Site-specific, stoichiometrically defined conjugation” to create stable single-label antibody constructs is more specific than typical random conjugation.

3) Combination of (single-lysine 1:1 conjugation + oligomeric human IgG + anti-label secondary antibody detection)

The claim is an ensemble: avoiding one element may not be enough if other elements still fall within the remaining claim language.

Practical Competitive Scenarios

Scenario A: Competitor keeps bridging format but changes conjugation chemistry

If a competitor uses random labeling or non-lysine conjugation, it may fall outside the “1:1 conjugate via a single lysine residue” limitation.
The closer the competitor gets to defined lysine site-specific conjugation and defined stoichiometry, the greater the risk.

Scenario B: Competitor uses oligomeric IgG but runs different concentrations

The claim contains a numeric range for final oligomeric IgG.
If an accused assay uses oligomeric IgG outside 10 to 1000 µg/mL, it can avoid literal coverage.

Scenario C: Competitor uses different hapten/detection architecture

Claim 1 does not mandate digoxygenin or biotin-streptavidin, but dependent claims do.
Even if Claim 1 is avoided, Claim 3-4 can still be avoided by using other labels or binding pairs.

Scenario D: Competitor reads tracer directly

Claim 1 requires an anti-detectable-label antibody step with a second label. Direct tracer detection likely avoids.

Infringement Risk Map by Claim Element

Claim element	Literal requirement	Main design-around pressure point
Capture & tracer reagents are 1:1 conjugates via single lysine	Specific conjugation mode + stoichiometry	Move to heterogeneous labeling or different conjugation chemistry; avoid “1:1 single-lysine”
Capture & tracer used at 0.5 to 10 µg/mL	Numeric mass band	Run outside range
Incubation time 0.5 to 24 hours	Numeric time band	Run outside range
Serum matrix 1% to 20%	Numeric matrix band	Change serum percentage
Oligomeric human IgG supplemented to 10 to 1000 µg/mL	Specific blocker + numeric band	Use different blocker or different concentration
Immobilize via binding pair	Capture member to solid-phase member	Use different immobilization strategy
Incubate with anti-detectable-label antibody with second detectable label	Requires anti-label secondary step	Direct readout or alternative detection
Dependent: biotin-streptavidin + digoxygenin	Specific binding pair + label	Switch hapten and/or immobilization pair
Dependent: drug = tocilizumab	Therapy-specific scope	Use non-tocilizumab target (or structural differences if scope is limited)

Litigation and Prosecution Posture: What the Claim Wording Suggests

The claim set uses typical ADA assay patent drafting patterns, but includes additional constraints that usually signal:

prior art likely existed around generic bridging assays and generic interference suppression,
novelty likely resided in the specific blocker type and concentration, and the defined conjugation architecture.

The mention of “interference-suppressed” is not a generic functional claim. It is tied to oligomeric human IgG supplementation, which tends to reduce the claim’s susceptibility to “result-dominated” invalidity attacks compared with assays that claim interference suppression without specifying how.

Key Takeaways

US 10,168,326 claims a specific bridging ADA immunoassay design with lysine-based 1:1 capture and tracer conjugates, oligomeric human IgG interference suppression (10 to 1000 µg/mL), and a required anti-detectable-label secondary antibody readout.
The highest competitive leverage lies in the combination of three limitations: single-lysine 1:1 conjugation, oligomeric human IgG at the stated concentration band, and anti-label secondary detection.
Dependent claims narrow further to biotin/streptavidin and digoxygenin labeling and to tocilizumab as the target drug antibody.
A landscape view should treat the patent as less about “ADA assays generally” and more about a tightly specified assay recipe. Most competitive risk comes from designs that replicate that recipe rather than just adopting the same high-level assay concept.

FAQs

1) Does Claim 1 require digoxygenin?
No. Digoxygenin appears only in dependent Claim 3. Claim 1 requires “detectable label” and detection via an anti-detectable-label antibody bearing a second label.

2) Is oligomeric human IgG the only interference suppression mechanism claimed?
Yes. The claim ties interference suppression to adding oligomeric human IgG to 10 to 1000 µg/mL prior to incubation.

3) What is the most important “literal” limitation for design-around?
The requirement that both capture and tracer reagents are 1:1 conjugates via a single lysine residue.

4) Can competitors avoid the biotin-streptavidin and digoxygenin dependent claims by changing labels?
Yes. Claims 3 and 4 are specific to biotin-streptavidin and digoxygenin. Using different hapten systems and/or different immobilization pairings can avoid those dependent claims.

5) What makes the tocilizumab scope commercially sensitive?
Claim 7 makes tocilizumab the drug antibody in the IL-6R class. Assay systems marketed for tocilizumab ADA monitoring face the closest alignment with this patent’s dependent scope.

References

[1] United States Patent 10,168,326.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125276	January 08, 2010	⤷ Start Trial	2036-03-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	October 21, 2013	⤷ Start Trial	2036-03-23
Genentech, Inc.	ACTEMRA	tocilizumab	Injection	125472	November 19, 2018	⤷ Start Trial	2036-03-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,168,326

Summary for Patent: 10,168,326